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Institute, Buffalo, New York, United States of America

Abstract
Arsenic trioxide (ATO) has been tested in relapsed/refractory multiple myeloma with limited success. In order to better
understand drug mechanism and resistance pathways in myeloma we generated an ATO-resistant cell line, 8226/S-ATOR05,
with an IC50 that is 2–3-fold higher than control cell lines and significantly higher than clinically achievable concentrations.
Interestingly we found two parallel pathways governing resistance to ATO in 8226/S-ATOR05, and the relevance of these
pathways appears to be linked to the concentration of ATO used. We found changes in the expression of Bcl-2 family
proteins Bfl-1 and Noxa as well as an increase in cellular glutathione (GSH) levels. At low, clinically achievable
concentrations, resistance was primarily associated with an increase in expression of the anti-apoptotic protein Bfl-1 and a
decrease in expression of the pro-apoptotic protein Noxa. However, as the concentration of ATO increased, elevated levels
of intracellular GSH in 8226/S-ATOR05 became the primary mechanism of ATO resistance. Removal of arsenic selection
resulted in a loss of the resistance phenotype, with cells becoming sensitive to high concentrations of ATO within 7 days
following drug removal, indicating changes associated with high level resistance (elevated GSH) are dependent upon the
presence of arsenic. Conversely, not until 50 days without arsenic did cells once again become sensitive to clinically relevant
doses of ATO, coinciding with a decrease in the expression of Bfl-1. In addition we found cross-resistance to melphalan and
doxorubicin in 8226/S-ATOR05, suggesting ATO-resistance pathways may also be involved in resistance to other
chemotherapeutic agents used in the treatment of multiple myeloma.
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One such malignancy since investigated is multiple myeloma
(MM) [6], characterized by uncontrolled growth of antibody
secreting plasma cells. At clinically achievable concentrations,
ATO has been shown to induce growth arrest and apoptosis in
malignant plasma cells isolated from MM patients as well as
established MM cell lines [7–10]. Additionally, ATO exhibited
modest activity against MM both as a single agent and in
combination with ascorbic acid and +/2 dexamethasone or
bortezomib in Phase I/II clinical trails [11–15].
The mechanism of action whereby arsenic trioxide exerts its
anti-myeloma activity has been shown to be multimodal in nature.
Research studies conducted in our laboratory and by others have
implicated intracellular thiol depletion, increased production of
reactive oxygen species, and induction of the intrinsic apoptotic
cascade as key events in ATO-induced apoptosis [9] [16–22].
However the molecular mechanisms that control these changes
remain unclear. Therefore to gain a better understanding of how
arsenic kills myeloma cells we have investigated the mechanisms
associated with acquired ATO resistance. Here we present data on

Introduction
Arsenic is a naturally occurring metalloid responsible for water
and crop contamination in several countries worldwide, giving rise
to a significant toxicological risk [1]. Paradoxically, arsenic is also a
highly effective therapeutic agent, used in several traditional
Chinese medical treatments [2]. Arsenic trioxide (As2O3, ATO) is
an inorganic arsenical recognized in the last 20 years for its
chemotherapeutic value. In 1990s, Chinese investigators published
the results of a clinical trial that revealed ATO to have significant
activity in acute promyelocytic leukemia (APL) [1]. The effectiveness of ATO against APL hinges on the binding of ATO to
cysteines in the PML portion of the PML-RARa fusion protein,
which is present in greater than 95% of all patients diagnosed with
APL [3]. This binding event leads to the degradation of the PMLRARa fusion protein, resulting in terminal differentiation and/or
the induction of apoptosis [4]. In the years following the Chinese
trial, several studies conducted in the United States confirmed the
efficacy of treating APL with ATO and also raised the possibility of
ATO use in other cancers [5].
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8226/S-ATOR05, an arsenic trioxide resistant multiple myeloma
cell line. Using gene expression profiling data, as well as previously
published information on arsenic-induced pathways to guide our
investigation, we identified two main pathways involved in ATO
resistance in the 8226/S myeloma cell line. Our results indicate
the involvement of the Bcl-2 family of proteins in controlling
apoptosis at low, clinically relevant concentrations while the
glutathione homeostasis pathway is important for continued
viability and proliferation at high concentrations.

Cellular Assays
ATO was removed from the culture medium of resistant cells
24 h prior to the set up of all experiments. Cells were incubated at
2.56105 cells/mL in supplemented RMPI1640 media as previously described [21] and treated with the indicated concentrations
of ATO, SGLU, melphalan, doxorubicin, bortezomib, or ABT737 for 24 h unless otherwise indicated and cell death was
determined by Annexin V-FITC/PI staining, and where indicated
cell pellets were frozen for protein analysis by Western blot. Cells
used for the determination of resistance sustainability were
cultured in the absence of arsenic for the indicated time periods
before being treated with drug or collected for GSH determination.

Materials and Methods
Cell Line
RPMI-8226 (8226/S) cells were purchased from American
Type Culture Collection (ATCC, Manassas, VA). Cells were
cultured in RPMI1640 medium, supplemented with 10% heat
inactivated fetal bovine serum, 5 mM HEPES, 2 mmol/L of Lglutamine, 100 mg/mL of streptomycin, and 100 units/mL of
penicillin (all purchased from Cellgro, Mediatech, Herndon, VA).
Cells were maintained at 37uC in a humidified atmosphere
containing 5% CO2.

Western Blot Analysis
Western Blot analysis was performed using standard techniques
as previously described [21].

Total Arsenic Determination
Intracellular elemental arsenic concentrations were determined
as previously described [24].

Generation of Arsenic Trioxide Resistant Cells

Intracellular Glutathione Assay

8226/S cells were initially treated with 50 nM of arsenic
trioxide (ATO) and allowed to reach 50% viability before the
concentration was increased. Thereafter the concentration was
gradually increased each week reaching a final concentration of
1 mM ATO. 8226/S cells grown along side the resistant cell line in
the absence of drug (8226-CR) and the parental cell line were used
as controls.

GSH concentration was determined using the Glutathione
Assay Kit (354102) from Calbiochem per manufacturer’s instructions. In order to relate GSH concentration to overall protein
level, BCA protein assay (Pierce) was performed along side each
GSH assay.

Gene Expression Profiling
Total RNA was isolated from 8226/S, 8226/S-CR, and 8226/
S-ATOR05 cells using the RNeasyH Mini Kit (Qiagen, Valencia,
CA) and the hybridization and initial data analysis performed by
Expression Analysis Inc. (Durham, NC). Total RNA quality was
confirmed using an Agilent 2100 Bioanalyzer and cRNA was
generated for probing Affymetrix Hu133 2.0 Plus Chips containing over 50,000 (54,675 including controls) probe sets. Affymetrix
GCOS software was used with statistical algorithms to determine a
quantitative value (signal intensity) and a qualitative value [present
(P) or absent (A) calls] for each transcript on the array. Signal
intensities for each cell line were considered only if at least one
present call, as qualitative value, was reported for any time point
and at least one signal was higher than 100. Data were analyzed
using Microsoft Excel and the bioinformatic programs Cluster and
TreeView (Eisen Laboratory, University of California, CA) as
previously described [21] [25].

Reagents
Arsenic Trioxide was provided by Cell Therapeutics Inc
(Seattle, WA). S-dimethylarsino-glutathione (SGLU, Darinaparsin,
DAR) was provided by Ziopharm Oncology. Melphalan and
Doxorubicin were purchased from Sigma-Aldrich. Bortezomib
(VelcadeH) was provided by Millennium Pharmaceuticals (Cambridge, MA). ABT-737 was provided by Abbott Laboratories
(Abbott Park, IL). Metaphosphoric acid (MPA) used in the GSH
assay was purchased from Sigma-Aldrich.

Antibodies
Primary antibodies used are as follows: rabbit anti-HO-1
polyclonal antibody (pAb) (Santa Cruz Biotechnology, Santa
Cruz, CA), rabbit anti-Nrf2 pAb (Santa Cruz Biotechnology),
rabbit anti-Keap1 pAb (Proteintech Group Inc., Chicago, IL),
mouse anti-NQO1 monoclonal antibody (mAb) (Cell Signaling,
Danvers, MA), rabbit anti-actin pAb (Sigma-Aldrich), mouse antiNoxa mAb (Abcam, Cambridge, MA), rabbit anti-Puma pAb (Cell
Signaling), rabbit anti-Bim pAb (Chemicon International Inc,
Temecula, CA), rabbit anti-Mcl-1 pAb (Stressgen Biotechnologies
Corporation, Victoria, BC, Canada), rabbit anti-Bcl-xL pAb (13.6)
[23], and rabbit anti-Bfl-1 pAb kindly provided by Dr. Borst, The
Netherland Cancer Institute. The following secondary antibodies
were used: ECL Rabbit or Mouse IgG, HRP-linked Whole Ab
(from donkey) (GE Heatlhcare, Piscataway, NJ), and the antimouse IgG1-HRP conjugate (Santa Cruz Biotechnology).

Real-Time PCR
Total RNA was extracted from parental, CR, and resistant cells
at the time points indicated using the RNeasy Mini Kit (Qiagen).
One microgram of total RNA, MuLV Reverse Transcriptase, and
random hexamer primers from the GeneAmp RNA PCR Kit
(Applied Biosystems) were used to generate cDNA. Subsequent
cDNA was amplified using the 206 human Noxa mix (PMAIP1,
Hs00560402_m1) or Bfl-1 mix (BCL2A1, Hs00187845_m1) and
the TaqMan Gene Expression Assay (Applied Biosystems) on the
7700 Sequence Detection System following the manufacturer’s
protocol. TaqMan human GAPDH (402869) was used as an
internal control and target mRNA expression was calculated
relative to untreated parental control, using GAPDH to normalize
RNA expression.

Cell Death Determination
Cell death was measured using Annexin V-Fluorescein Isothiocyanate (FITC) (Biovision, Palo Alto, CA) and PI as previously
described [19].
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ATO for 24 hours and the level of elemental arsenic present in
each cell line was determined. We found no significant difference
in the intracellular concentration of arsenic between the parental,
CR, and resistant cell lines (Fig. 1B).
Additionally we analyzed gene expression profiling data for
these cells to determine if arsenic resistance in 8226/S-ATOR05
was associated with changes in the expression of any ABC
transporters (Table 1). We were unable to correlate any changes in
pump expression to arsenic resistance, indicating resistance is not
due to an increase in the expression of drug efflux pumps.
Together these data suggest that ATO resistance in 8226/SATOR05 cells is due to biochemical changes in arsenic response
pathways and not to changes in uptake or efflux of ATO or its
metabolites.

Results
8226/S Cell Line can Acquire Resistance to Arsenic
Trioxide
In order to better understand the mechanisms governing the
anti-myeloma activity of ATO, we generated an ATO resistant
cell line. We attempted to generate four arsenic resistant lines,
using KMS11, MM.1s, U266, and 8226/S myeloma cell lines,
however we were only able to successfully produce a resistant cell
line in 8226/S (8226/S-ATOR05). To control for changes that
are the result of the time required for the selection, we cultured
cells in the absence of arsenic parallel to the selected cells. These
cells are referred to as control resistant (CR) cells. Figure 1A
represents a 24 hour dose curve with 8226/S, 8226/S-CR, and
8226/S-ATOR05 cell lines. The parental and CR cell lines exhibit
a similar apoptotic dose response with IC50s of 3.46 mM and
2.93 mM respectively. In contrast, the IC50 for 8226/S-ATOR05
is 2–3-fold higher than the control cell lines at 8.85 mM,
representing a statistically significant resistance to ATO that is
well beyond clinically achievable concentrations.
In order to verify that arsenic resistance in 8226/S-ATOR05 is
not simply due to lack of arsenic transport, we performed arsenic
uptake assays. Control and resistant cells were treated with 2 mM

The Antioxidant Response Remains Unchanged While
the Apoptotic Response is Altered in Cells that have
Acquired ATO Resistance
We next turned our attention to changes in previously
documented responses to ATO treatment – the antioxidant
response and the apoptotic response. We have previously
documented the activities of the antioxidant response through
the stabilization of the transcription factor Nrf2 following ATO
treatment of myeloma cell lines [25]. Nrf2 regulates the expression
of many genes that protect cells from oxidative damage, including
heme oxygenase-1 (HO-1) and NAD(P)H dehydrogenase quinone
1 (NQO1) [26]. Therefore we determined if the anti-oxidant
response was altered in ATOR05 cell by measuring expression of
Nrf2 and its targets, NQO1 and HO-1. Surprisingly we did not see
any effect on the basal expression of any of these proteins or the
Nrf2 regulator KEAP1 (Figure 2A). Additionally, following ATO
addition, the anti-oxidant response was similar in all three cell lines
as Nrf2, NQO1 and HO-1 were all induced (Figure 2A). While
these data demonstrate that the ATOR05 cells respond to ATO
treatment, they also suggest that the Nrf2-dependent anti-oxidant
response plays little role in the activity of ATO in myeloma cells.
Changes in the expression pattern of pro-apoptotic BH3-only
proteins are also part of the response to ATO treatment of MM
cells. We, and others, previously demonstrated the importance of
BH3-only proteins Noxa, Bim, and Bmf in arsenic-induced
apoptosis [21] [27]. We did not see significant differences in the
baseline levels of the anti-apoptotic proteins Bcl-xL and Mcl-1 or
the BH3-only proteins Bim and Puma. However, Noxa levels
appeared lower in the ATO-resistant cells and the induction of
Noxa and Puma was diminished following ATO-treatment
(Figure 2B).
In order to further investigate the role of the Bcl-2 family of
proteins in acquired arsenic resistance, we performed gene
expression profiling on parental, CR, and resistant untreated cells
(Fig. 2C). Analysis of these data revealed changes in the regulation
of both pro- and anti-apoptotic genes. Consistent with what was
observed in Figure 2B, mRNA levels of BH3-only proteins Noxa
and Puma were down-regulated 4- and 2-fold respectively.
Interestingly the anti-apoptotic Bfl-1 was up-regulated 4-fold.
Western blot analysis was performed in order to confirm if these
changes were also present at the protein level. As seen in
Figure 2D, a decrease in the expression of Noxa and an increase in
the expression of Bfl-1 are observed at the protein level in the
arsenic resistant cell line 8226/S-ATOR05. While baseline Puma
expression was lower in ATOR05 cells compared to parental cells,
induction remained intact (Figure 2D).

Figure 1. 8226/S-ATOR05 cell line is resistant to ATO and
resistance is not due to changes in uptake. (A) 8226/S, 8226/S-CR,
8226/S-ATOR05 cell lines were treated with the indicated concentrations of ATO for 24 h and apoptosis was assessed by flow cytometry
using Annexin V-FITC and PI staining and graphed as percent of control
Annexin V positive cells versus drug concentration. (B) 8226/S, 8226/SCR, 8226/S-ATOR05 cells were treated with 2 mM ATO for 24 h and then
collected for intracellular arsenic determination. The data are presented
as the mean 6 SD of at least 3 independent experiments. Student’s ttest was used to compare differences between 8226/S and 8226-CR and
8226/S-ATOR05 cells, with 95% confidence intervals. *, P,0.05; **,
P,0.01; ***, P,0.001.
doi:10.1371/journal.pone.0052662.g001
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Table 1. ABC genes relative expression.

8226/S-ATOR05

8226/S-ATOR05

NO ATO 23 d

NO ATO 50 d

ABC Genes

Alias

8226/S

8226/S-CR

8226/S-ATOR05

ABCA1

ABC1

1.00

1.35

1.21

1.15

1.37

ABCA2

ABC2

1.00

0.74

0.99

0.98

0.94
0.68

ABCA7

1.00

0.92

0.82

0.73

ABCB6

MTABC3

1.00

0.75

1.04

1.73

0.96

ABCB7

ABC7

1.00

1.46

1.19

0.99

1.09

ABCB8

MABC1

1.00

1.35

1.40

1.54

1.77

ABCB10

MTABC2

1.00

1.23

0.94

0.87

0.84

ABCC1

MRP1

1.00

1.19

1.45

1.66

1.48

ABCC4

MRP4

1.00

0.88

0.99

0.80

0.93

ABCC5

MRP5

1.00

1.04

0.76

0.65

0.57

ABCC10

MRP7

1.00

0.97

1.00

1.05

0.94

ABCD1

ALD

1.00

1.85

3.20

4.62

3.80

ABCD3

PXMP1,PMP70

1.00

1.03

0.79

0.73

0.90

ABCD4

PMP69, P70R

1.00

0.77

0.94

1.06

1.07

ABCE1

OABP, RNS4I

1.00

1.05

1.04

0.99

0.94

ABCF1

ABC50

1.00

1.05

1.15

1.13

1.25

ABCF2

1.00

0.93

1.14

0.96

1.15

ABCF3

1.00

1.24

1.07

1.18

1.31

ABCG1

ABC8, White

1.00

0.73

1.17

1.19

0.68

ABCG2

ABCP, MXR, BCRP

1.00

0.89

0.55

0.64

0.60

Genes associated to drug resistance are in bold. Genes that were not expressed are not listed.
doi:10.1371/journal.pone.0052662.t001

genes associated with glutathione metabolism and their relative
expression based on gene expression profiling. Most genes
associated with GSH synthesis or utilization were either
unchanged or displayed a change of less than 50% when
compared to the parental line (Table 2). However four genes
were upregulated by acquisition of resistance to arsenic and
returned to baseline following arsenic removal that also resulted in
a return to baseline GSH levels (see below). While two of these
genes are involved in the use of GSH (GSTM1, MGST3), the
other two genes encode proteins that could result in increased
GSH levels. Esterase D (ESD) is a serine hydrolase that is involved
in formaldehyde detoxification. It catalyzes the hydrolysis of Sformylglutathione to GSH and formate [30]. However it is
unlikely that these cells contain significant levels of S-formylglutathione. In contrast the fourth gene that is upregulated in 8226/
S-ATOR05 and returns towards baseline when the cells are
removed from selection is required for de novo GSH synthesis.
Glutathione synthetase (GSS) catalyzes the final step in GSH
synthesis [31] and is 1.48-fold higher in ATOR05 cells.

Glutathione Levels in 8226/S-ATOR05 Cells are
Significantly Increased as Compared to Control Cell Lines
The role of glutathione (GSH) in arsenic metabolism and
detoxification is well established [28], as well as the role of
increased intracellular glutathione in drug resistance [29].
Therefore we next determined the level of intracellular GSH
present in the resistant cell line, as compared with the controls.
Data presented in Figure 3A verify a significant increase in the
amount of intracellular GSH present in 8226/S-ATOR05 when
compared to either 8226/S or 8226/S-CR. On average, resistant
cells contained 79.59 nmol GSH/mg of protein, whereas the
control and control resistant cells contained 39.45 and 37.91 nmol
GSH/mg protein, respectively.
In order to determine if this increase in intracellular GSH is
important for establishing resistance to ATO, we treated parental,
control resistant, and resistant cells with either buthionine
sulfoximine (BSO) or N-acetyl-cysteine (NAC) for 24 hrs. BSO
inhibits the rate-limiting enzyme in GSH synthesis, c-glutamate
cysteine ligase, blocking production, whereas NAC increases the
available intracellular cysteine thereby boosting GSH production.
Increasing GSH concentration through NAC treatment allowed
8226/S and 8226/S-CR cells to survive in the presence of ATO at
viabilities comparable to that of resistant cells treated with ATO
alone. In contrast NAC had no effect on ATO-induced apoptosis
in the ATO-resistant cells. However, treating resistant cells with
ATO and BSO resulted in significant cell death, underlining the
importance of glutathione in arsenic resistance.
Next we wanted to determine if the baseline GSH increase in
resistant cells was due to changes in the transcription of genes
involved in glutathione homeostasis. Table 2 lists the expressed

PLOS ONE | www.plosone.org

Removal of Arsenic Selection Results in Loss of
Resistance Phenotype
To determine if arsenic resistance in 8226/S-ATOR05 cells is
dependent upon the selective pressure of arsenic, 24 h dose curves
were performed on parental, CR, and resistant cells cultured in the
absence of ATO for 7, 14, 21, 35, and 50 days (Figure 4A). At the
highest concentration tested (8 mM), changes in sensitivity were
observed as early as 7 days after ATO withdrawal, however
sensitivity to a clinically relevant concentration (2 mM) was not
observed until 50 days following ATO withdrawal. These data
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Figure 2. The antioxidant response is unchanged in 8226/S-ATOR05 cells while the expression of Bcl-2 family members is altered.
8226/S, 8226/S-CR, 8226/S-ATOR05 cells were treated with 2 mM ATO for 0, 6, or 24 h, protein expression was determined by Western blot and
membranes were probed with antibodies against proteins involved in the (A) antioxidant response or (B) the Bcl-2 family. (C) A heatmap of Bcl-2
genes expressed in 8226/S cells. The scale represents the change relative to the median expression for each gene. (D) Protein expression of Noxa and
Bfl-1 was determined by Western blot in 8226/S, 8226/S-CR, 8226/S-ATOR05 control cells. Actin expression demonstrates protein loading.
Quantitation of changes in Noxa and Puma are provided. The data are normalized to actin and presented as fold change relative to untreated
parental cells.
doi:10.1371/journal.pone.0052662.g002
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Figure 3. The intracellular GSH level is elevated in 8226/S-ATOR05 cells and is important for arsenic resistance. (A) 8226/S, 8226/S-CR,
8226/S-ATOR05 control cells were harvested and the intracellular GSH concentration was determined using the Glutathione Assay kit from
Calbiochem. (B) 8226/S, 8226/S-CR, 8226/S-ATOR05 cells were treated with 2 mM ATO alone or in combination with either 100 mM BSO or 10 mM NAC
for 24 h and apoptosis was determined using flow cytometry. Data are graphed as percent of control Annexin V positive cells. Mean 6 SD of at least 3
independent experiments. **, P,0.01.
doi:10.1371/journal.pone.0052662.g003

the fate of Noxa and Bfl-1 expression in this transition. Gene
expression was determined using Real Time qPCR, including
samples from resistant cells cultured in the absence of arsenic for 1,
7, 14, 21, 35, and 50 days. Figure 4C shows a dramatic increase in
the level of Bfl-1 mRNA in 8226/S-ATOR05 cells. This
expression decreases by approximately 50% as cells are maintained in arsenic-free culture medium, but it never returns to
control levels. Noxa levels were lower in the ATOR5 cells,
however they increased minimally after arsenic removal (not
shown). Taken together these data presented suggest that a
gradual decrease in GSH levels as well as a gradual decrease in
Bfl-1 expression and a modest increase in Noxa levels collaborate
to return ATO sensitivity to 8226/S-ATOR05 cells in the absence
of arsenic selectivity.
These data suggest a possible relationship between the level of
intracellular GSH, the expression of Bfl-1/Noxa and arsenic
sensitivity. To test if a correlation exists, we compared intracellular
GSH concentrations (Figure 5A) and Bfl-1 expression (Figure 5B)

suggest that the changes associated with high level resistance are
exquisitely dependent upon the sustained presence of arsenic while
resistance to clinically relevant levels of arsenic can still be
observed for an extended period following removal.
In order to determine if this loss of resistance was associated
with changes in GSH levels, we examined the levels of intracellular
GSH in 8226/S-ATOR05 cells cultured in the absence of ATO
for 7, 14, 21, 35, and 50 days (Figure 4B). The level of intracellular
GSH decreased in a time dependent fashion following arsenic
removal, with no significant difference in GSH concentration
compared to the control cell lines by 21 days out. These data
suggest that the presence of arsenic is required to maintain
increased GSH production and high level resistance in the ATO
resistant cells.
As presented in Figure 2, changes in the expression of Noxa and
Bfl-1 may also contribute to the arsenic resistant phenotype. Given
that removal of arsenic from the culture medium leads to a gradual
return to sensitivity at therapeutic levels, we wanted to determine

PLOS ONE | www.plosone.org
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Table 2. Relative expression of GSH-associated genes.

Gene Descriptor

Gene Symbol

8226/S

8226/S8226/S-CR 8226/S-ATOR05 ATOR05

Cystathionase (cystathionine gamma-lyase)

CTH

1.00

1.36

0.49

8226/S-ATOR05

NO ATO 23 d

NO ATO 50 d

0.42

0.70

Esterase D/formylglutathione hydrolase

ESD

1.00

0.95

1.58

1.33

1.24

Gamma-glutamyltransferase 1

GGT1

1.00

0.82

0.96

0.93

0.96
1.26

Glutamate-cysteine ligase, catalytic subunit

GCLC

1.00

1.02

1.08

1.14

Glutamate-cysteine ligase, modifier subunit

GCLM

1.00

1.22

0.95

0.98

1.47

Glutathione peroxidase 1

GPX1

1.00

1.46

0.77

1.18

0.75

Glutathione peroxidase 4

GPX4

1.00

1.00

1.32

1.04

0.80

Glutathione peroxidase 7

GPX7

1.00

0.50

0.74

1.02

0.75

Glutathione reductase

GSR

1.00

0.86

1.27

1.63

1.49

Glutathione S-transferase A4

GSTA4

1.00

0.93

1.87

2.17

1.55

Glutathione S-transferase kappa 1

GSTK1

1.00

0.86

1.13

1.00

0.78

Glutathione S-transferase M1

GSTM1

1.00

0.93

1.71

1.31

1.00

Glutathione S-transferase M2 (muscle)

GSTM2

1.00

0.93

1.38

1.28

1.36

Glutathione S-transferase omega 1

GSTO1

1.00

0.82

1.01

0.88

0.79

Glutathione S-transferase theta 1

GSTT1

1.00

0.73

0.71

0.72

0.65

Glutathione S-transferase, C-terminal domain containing

GSTCD

1.00

1.06

0.92

1.03

1.24

Glutathione synthetase

GSS

1.00

0.71

1.48

1.37

1.12

Glutathione transferase zeta 1

GSTZ1

1.00

1.09

0.83

1.14

1.26

Hydroxyacylglutathione hydrolase

HAGH

1.00

0.98

0.56

0.86

0.67

Hydroxyacylglutathione hydrolase-like

HAGHL

1.00

1.05

1.40

1.19

0.98

Malic enzyme 1, NADP(+)-dependent, cytosolic

ME1

1.00

0.91

1.07

1.05

1.07

Malic enzyme 2, NAD(+)-dependent, mitochondrial

ME2

1.00

0.79

0.72

0.63

0.50

Malic enzyme 3, NADP(+)-dependent, mitochondrial

ME3

1.00

0.60

0.79

0.94

1.47

Microsomal glutathione S-transferase 1

MGST1

1.00

0.94

1.03

0.93

0.96

Microsomal glutathione S-transferase 2

MGST2

1.00

0.68

0.96

1.49

1.48

Microsomal glutathione S-transferase 3

MGST3

1.00

0.69

1.62

1.15

1.21

Serine hydroxymethyltransferase 1 (soluble)

SHMT1

1.00

1.22

1.01

1.23

1.09

Serine hydroxymethyltransferase 2 (mitochondrial)

SHMT2

1.00

1.01

0.97

0.92

0.91

Serine palmitoyltransferase, long chain base subunit 2

SPTLC2

1.00

1.07

0.91

1.34

1.36

Solute carrier family 7, member 11

SLC7A11

1.00

0.85

0.67

0.56

0.94

Expression is relative to the parental cell line 8226/S. Changes in expression greater or equal to 1.4 are highlighted in bold. Genes changes that are associated with the
ATO-resistant phenotype are shown in bold and italics.
doi:10.1371/journal.pone.0052662.t002

change in the apoptotic threshold associated with increased Bfl-1
also contributed to the response.
To further test the role of GSH in acquired ATO resistance, we
tested the effects of GSH depletion on both high and low
concentrations of ATO in the ATOR05 and control lines. Since
depletion of GSH with 100 mM BSO will sensitize both the
parental ATOR05 cells to 2 mM ATO (Figure 3B), we initially
titrated the BSO to the lowest concentration that had a significant
effect in the parental cells treated with 2 mM ATO. This allowed
us to observe differences in the effects of BSO on increasing
concentrations of ATO. We found that we could use as little as
1 mM BSO to sensitize the parental cells to 2 mM ATO while
having little effect in ATOR05 (Figure 5C and data not shown). In
the parental cell line the addition of BSO had a significant impact
on ATO-induced apoptosis at all concentrations of ATO tested at
48 h (Figure 5C). Similar results were observed for the CR line
however the effect of BSO was not significant at 8 mM (P = 0.06).

observed during the 50 day time course following ATO removal to
the sensitivity to arsenic at each time point. This analysis revealed
an inverse correlation between intracellular GSH level or Bfl-1
expression and arsenic sensitivity. No correlation was observed
with Noxa expression (not shown). Interestingly these correlations
were stronger at different concentrations of ATO. In the case of
GSH, this inverse correlation is nearly linear at 8 mM ATO, while
at the more clinically relevant concentration of 2 mM, the
association exists, however it is not as strong (R2 = 0.9537,
0.6346 respectively). In contrast a correlation exists at the lower
concentration of ATO and Bfl-1 expression (R2 = 0.73425) while
no correlation exists at the highest concentration (R2 = 0.24602).
Taken together with the temporal differences observed (intracellular GSH returns to baseline by 21 days while resistance persists
for an additional 29 days and Bfl-1 levels persist) these data suggest
that at high ATO concentrations, GSH is the primary contributor
to acquired resistance, while at clinically relevant concentrations a
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Figure 4. The ATO resistance phenotype is lost upon removal of arsenic. (A) 8226/S, 8226/S-CR, 8226/S-ATOR05 cells, as well as 8226/SATOR05 cells cultured in the absence of ATO for 7, 14, 21, 35, and 50 days were treated with the indicated concentrations of ATO for 24 h and
apoptosis was determined by flow cytometry and graphed as percent of control Annexin V positive cells versus drug concentration. Statistical
analysis compared to 8226/S are provided in the lower panel. (B) 8226/S, 8226/S-CR, 8226/S-ATOR05 control cells, as well as control cells from the
indicated time points were harvested and the intracellular GSH concentration was determined as described in the Materials and Methods. (C) Realtime PCR was performed on 8226/S, 8226/S-CR, 8226/S-ATOR05 cells, as well as 8226/S-ATOR05 cells cultured in the absence of ATO for 7, 14, 21, 35,
and 50 days to determine the expression patterns of Bfl-1. Data is graphed using the Delta CT, which represents the number of cycles needed to
reach threshold, normalized against GAPDH. High delta Ct values represent low expression while low delta Ct values indicate high expression. The
data in (B) and (C) are presented as the mean 6 SD of at least 3 independent experiments. Student’s t-test was used to compare differences between
8226/S-ATOR05 and all other cell lines, with 95% confidence intervals. *, P,0.05; **, P,0.01; ***, P,0.001, No difference (ND).
doi:10.1371/journal.pone.0052662.g004

single line, 8226-ATOR05. This suggests that arsenic targets
critical pathways for myeloma cell survival. Therefore understanding these pathways could provide insight into how to better
target the disease. Acquired resistant lines have been useful for
determining both drug targets through loss of function changes as
well as compensatory mechanisms of resistance. Our data suggest
there are two pathways involved in arsenic resistance in 8226/SATOR05 cells and the importance of each pathway is predicated
on ATO concentration. At lower, clinically relevant, concentrations the primary mechanism responsible for resistance appears to
be alterations in the expression of two Bcl-2 family members, Bfl-1
and Noxa, whereas elevated levels of intracellular GSH are
required for resistance to super-clinical doses.
The role of GSH in drug metabolism, and specifically arsenic
metabolism is well documented. Based on previous studies it is not
surprising that we found an elevated level of intracellular GSH in
our ATO resistant cell line [29]. However what is intriguing is the
apparent dose dependent role. GSH is thought to be important for
maintaining the intracellular redox status in response to ATO as
well as direct binding and export of the arsenic molecule. Our
laboratory has previously shown that the production of ROS in
response to ATO treatment is not important for the induction of
apoptosis, suggesting the primary role GSH plays in 8226/SATOR05 is one of detoxification rather than antioxidant defense
[25]. Consistent with these findings, we observed no changes in the
Nrf2 anti-oxidant pathway associated with acquired resistance to
ATO. Therefore it is understandable that the requirement for
GSH is much higher when the intracellular level of arsenic is high.
The cell would need to be highly efficient at neutralizing and
removing excess arsenic so that the survival pathways are not
overwhelmed. This is further supported by the fact that GSH
levels return to baseline rapidly upon the removal of arsenic
selection. In our previous studies of the myeloma response to
arsenic trioxide we found that numerous genes involved in de novo
GSH synthesis as well as the GSH salvage pathway were upregulated within 24 h of ATO treatment [25]. Surprisingly none
of these genes were found to be up-regulated in ATOR05 cells.
These genes were all associated with the Nrf2 response which is
not elevated during acquired resistance, therefore this finding is
not surprising. However one gene in the de novo pathway is
modestly up-regulated and returns toward baseline expression
once the cells were removed from arsenic selection. While not the
rate-limiting step in GSH synthesis, GSS is required to link glycine
to the c-glutamyl-cysteine to complete the synthesis [31]. Both the
magnitude and temporal nature of the change in GSS expression
are consistent with the changes observed in GSH levels and would
be the most likely explanation for the increase in GSH levels
associated with acquisition of ATO resistance.
Bcl-2 family proteins are important regulators of the intrinsic
apoptotic cascade [32]. Alterations in the regulation or expression
of one or more of these proteins are a hallmark of many cancers
and often contribute to chemo-resistance [33]. Here we report
changes in the expression of two Bcl-2 family members, Bfl-1 and

This is likely due to the fact that almost all the cells are already
dead with ATO alone at this concentration. In contrast BSO has
no effect on ATO-induced apoptosis at 2 mM and is marginally
significant at 4 mM (p = 0.0479) in the ATO-resistant line.
However BSO has a highly significant (p = 0.0002) effect in these
cells when used in combination with 8 mM ATO. Together these
data support the conclusion that the primary role for increased
GSH is to protect ATO-resistant cells from high concentrations of
ATO.

ATO Resistant Cell Line 8226/S-ATOR05 also Displays
Resistance to Melphalan and Doxorubicin
In order to determine if acquisition of ATO resistance also
confers resistance to other commonly used or novel chemotherapeutic agents, we tested the sensitivity of parental, CR, and ATO
resistant cell lines to darinaparsin (S-dimethylarsino-glutathione,
SGLU), melphalan, bortezomib, ABT-737, and doxorubicin.
Figure 6A presents 24 h concentration curves with each drug, as
well as ATO. ATO resistant cells remain sensitive to the organic
arsenical darinaparsin (DAR), the proteasome inhibitor bortezomib, and the Bcl-2/xL inhibitor ABT-737, but show crossresistance to melphalan and doxorubicin. The concentration
curves of ATO and melphalan-treated resistant cells are very
similar, maintaining resistance at all concentrations investigated.
However, doxorubicin-treated ATO-resistant cells display resistance at low concentrations but become as sensitive as control cells
at the highest concentration tested. These data suggest that the
mechanism by which myeloma cells respond to melphalan is
similar to that of ATO, while the mechanism for doxorubicin
maybe more distantly related.
In order to determine if the resistance of 8226/S-ATOR05 to
melphalan and doxorubicin is dependent on the ATO resistant
phenotype, resistant cells were cultured in the absence of ATO for
7, 14, 21, 35, or 50 days, then treated with two concentrations of
each drug for 24 h (Figure 7). Cells treated with 30 mM melphalan
behaved in a manner similar to that of cells treated with ATO,
regaining sensitivity to drug as time from arsenic removal
increased, however treatment with 60 mM melphalan resulted in
significant apoptosis as early as 7 days out. These data indicate
arsenic-resistance mechanisms maybe overcome with high dose
melphalan. Interestingly, all variations of 8226-ATOR05 treated
with doxorubicin maintained resistance at both 1 and 2 mM drug.
These data suggest resistance to ATO and resistance to melphalan
are controlled by overlapping pathways, whereas an as of yet
uninvestigated pathway plays a role in doxorubicin and ATO
cross-resistance.

Discussion
In an effort to better understand drug action and resistance
mechanisms in multiple myeloma, we attempted to generate
arsenic resistant myeloma cell lines. Unfortunately after multiple
attempts in 4 different backgrounds we could only generate a
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Figure 5. GSH inversely correlates with response to high concentrations of ATO while Bfl-1 expression inversely correlates with the
response to clinically relevant ATO concentrations. GSH levels (A) or Bfl-1 expression (B) from Figure 4 was correlated with apoptosis data
from Figure 4. Pearson coefficient data are presented as a determinant of the strength of the correlation. (C) Cells were treated with the indicated
concentrations of ATO in the presence or absence of BSO (1 mM) and apoptosis determined at 24 and 48 h. The data are presented as the mean 6 SD
of at least 3 independent experiments. The lower panel provides the statistical analyses of the data (student’s t test).
doi:10.1371/journal.pone.0052662.g005
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Figure 6. ATO resistant cells are also resistant to melphalan and doxorubicin, but remain sensitive to darinaparsin, bortezomib and
ABT-737. 8226/S, 8226/S-CR, and 8226/S-ATOR05 cells were treated with the indicated concentrations of ATO, DAR, Mel, Bz, ABT-737 or Dox for 24 h
and apoptosis was assessed by flow cytometry and graphed as percent of control Annexin V positive cells vs. drug concentration. The data are
presented as the mean 6 SD of at least 3 independent experiments.
doi:10.1371/journal.pone.0052662.g006

Noxa, in our ATO resistant cell line. Bfl-1 is an anti-apoptotic
protein whose up-regulation contributes to chemo-resistance in Bcell chronic lymphocytic leukemia [34] as well as acquired
resistance to ABT-737 in diffuse large B-cell lymphoma cell lines
[35]. The up-regulation of Bfl-1 in 8226/S-ATOR05 is associated
with resistance to ATO at low concentrations and may play a role
PLOS ONE | www.plosone.org

with the increase in GSH to promote resistance at super-clinical
doses. Bfl-1 is an attractive candidate for an ATO resistance gene
as it can effectively bind to the pro-apoptotic BH3-only activator
protein Bim and is not inhibited by the BH3-sensitizers Noxa or
BMF [36]. We have previously shown that these three BH3-only
proteins are required for ATO-induced apoptosis in myeloma cell
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Figure 7. ATO and Melphalan resistance pathways overlap while Doxorubicin resistance pathway(s) may be related. 8226/S, 8226/SCR, 8226/S-ATOR05 cells, as well as 8226/S-ATOR05 cells cultured in the absence of ATO for 7, 14, 21, 35, and 50 days were treated with the indicated
concentrations of ATO, Mel, or Dox for 24 h and apoptosis was determined by flow cytometry and graphed as percent of control Annexin V positive
cells versus drug concentration. The data are presented as the mean 6 SD of at least 3 independent experiments.
doi:10.1371/journal.pone.0052662.g007

protein which is induced by ATO in myeloma is Puma. However
our previous studies indicated that Puma induction was not
required for ATO-induced apoptosis [21]. In our current studies
Puma baseline expression is lower in the ATO-resistant cells,
however consistent with a lack of a role for Puma in ATO-induced
death, Puma induction remains intact in ATOR05.
In addition to arsenic resistance, we have shown that 8226/SATOR05 cells are also resistant to melphalan and doxorubicin but
not to other agents including the organic arsenical darinaparsin.
This latter finding is consistent with our previous studies that
demonstrated that intracellular GSH levels were not as important
in regulating darinaparsin-induced death as they are for ATO
[24]. Melphalan and doxorubicin both function by damaging
DNA, acting as either an alkylating or intercalating agent,
respectively, ultimately inhibiting replication and inducing apoptosis in rapidly dividing cancer cells. While these mechanisms of
action differ from that of ATO our data suggest that either one or
both of the pathways responsible for arsenic resistance in 8226/SATOR05 cells are also involved in loss of sensitivity to Mel and
Dox. Further examination of the data suggest that perhaps
elevated intracellular GSH is important for resistance to melphalan as cells once again become sensitive to melphalan as GSH
levels decrease, similar to the pattern see with ATO. This is
consistent with the selection of melphalan resistance in the RPMI8226 background. The LR5 mutant was selected for melphalan
resistance and it also displays an increase in GSH levels [39–40].
The mechanism of resistance to doxorubicin appears to be at least
partially distinct from melphalan and even ATO as it is stable for
at least 50 days following ATO withdrawal. This is different than
what was observed when RPMI-8226 cells were selected for
doxorubicin resistance. The Dox40 mutant is primarily resistant to
doxorubicin because of up-regulation of p-glycoprotein and Bcl-xL
and are not resistant to ATO [41–42] [9]. Despite having activity,
the future use of ATO in the treatment of myeloma is not clear,
however it may prove to be an important tool for the study of
resistance mechanisms to drugs that remain as workhorses in the
treatment of this disease.

lines [21]. Interestingly Bfl-1 is the only known anti-apoptotic Bcl2 family member that is not inhibited by BMF and thus would
allow cells to overcome BMF induction by ATO. The mechanism
of Bfl-1 induction during acquisition of ATO resistance is not
addressed in the current study however it is interesting to note that
this is an established target of NF-kB signaling [37]. However
other NF-kB targets including Bcl-xL, cIAP2, and IkB are not
changed in these cells. Additionally none of the NF-kB genes
display altered expression in ATO-R05 cells (unpublished
observations). Finally bortezomib sensitivity is not altered in these
cells, therefore the mechanism does not appear to be related to
NF-kB regulation and warrants further investigation. Unfortunately silencing of Bfl-1 in ATOR05 was only modestly effective
making it very difficult to directly test the role of Bfl-1 in this model
(not shown). While the levels of Bfl-1 could be reduced by over
50% at the mRNA level, the cells still express much higher levels
than the parental or CR cells making the results of these studies
difficult to interpret. Regardless the up-regulation of anti-apoptotic
Bcl-2 proteins in myeloma cells can influence ATO-induced
apoptosis and up-regulation of Bfl-1 would be consistent with these
findings [9].
Noxa is a pro-apoptotic BH3-only member of the Bcl-2 family
that inhibits Mcl-1 [32] [36]. We have previously shown that Noxa
is up-regulated in response to ATO in multiple myeloma cells and
that it plays a pivotal role in the initiation of apoptosis in response
to arsenic [21] [24]. It is not surprising then that the loss of this
induction would contribute to ATO resistance. However the
apparent inverse relationship between Noxa and GSH is
interesting. We have shown that when myeloma cells are treated
with ATO, Noxa is induced, and when cells are treated with ATO
and NAC (to enhance GSH production) Noxa induction is
decreased. However when cells are treated with ATO and BSO (to
deplete GSH) Noxa induction is significantly increased [21]. It is
unlikely that Noxa induction is dependent upon ROS production,
as treating cells with ATO and then blocking ROS production
with BHA does not block Noxa up-regulation. Additionally
RPMI-8226 expresses a mutant form of p53 therefore the
induction is independent of this pathway [38]. A third BH3
PLOS ONE | www.plosone.org
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Finally, our data point to a potential problem with data
interpretation using acquired resistant lines to determine mechanism of action or resistance. While our line was generated using
clinically relevant arsenic levels (1 mM), it became resistant to
concentrations eight times higher. Our data suggest that the
important aspects of resistance to clinically achievable concentrations may differ from those required for ‘‘maximal’’ resistance and

caution should be taken in determining the appropriate mechanisms of resistance in these lines.
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